Nuvation Bio Inc. (NUVB)
NYSE · Biotechnology
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
Nuvation Bio Inc. is trading at $4.45, down 6.32% on the session. The 50 day average sits at $6.12 and the 200 day at $5.63, which puts the stock in a uptrend. RSI is at 26.3, which reads as oversold, and MACD is bearish crossover. Volume is above average.
The nearest support is around $4.63 with resistance near $5.83, so that band frames the current range. Average daily movement is roughly $0.28, or about 6.2% of the share price, which is what any stop placement has to allow for. The overall health score of 37 out of 100 combines a trend score of 30, momentum of 28 and a risk score of 62.
Technical indicators
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Company website